|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2002-6-17
|
|
pubmed:abstractText |
CCR3 antagonist leads with IC(50) values in the microM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC(50) values for CCR3.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amides,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CCL11 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CCR3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL11,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CC,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR3,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Chemokine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:CovingtonMaryanneM,
pubmed-author:DaviesPaulP,
pubmed-author:DeLuccaGeorge VGV,
pubmed-author:DeciccoCarl PCP,
pubmed-author:DunciaJohn VJV,
pubmed-author:EstrellaMelissaM,
pubmed-author:FriedmanSteven MSM,
pubmed-author:GardnerDaniel SDS,
pubmed-author:KoSoo SSS,
pubmed-author:NewtonRobert CRC,
pubmed-author:SantellaJoseph BJB3rd,
pubmed-author:SolomonKimberly AKA,
pubmed-author:StowellNicole CNC,
pubmed-author:TanabeKeiichiK,
pubmed-author:TrainorGeorge LGL,
pubmed-author:VarnesJeffrey GJG,
pubmed-author:WackerDean ADA,
pubmed-author:WadmanEric AEA,
pubmed-author:WatsonPaul SPS,
pubmed-author:WelchPatricia KPK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
8
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1785-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12067561-Alkylation,
pubmed-meshheading:12067561-Amides,
pubmed-meshheading:12067561-Anti-Asthmatic Agents,
pubmed-meshheading:12067561-Calcium,
pubmed-meshheading:12067561-Chemokine CCL11,
pubmed-meshheading:12067561-Chemokines, CC,
pubmed-meshheading:12067561-Chemotaxis, Leukocyte,
pubmed-meshheading:12067561-Humans,
pubmed-meshheading:12067561-Inhibitory Concentration 50,
pubmed-meshheading:12067561-Ligands,
pubmed-meshheading:12067561-Piperidines,
pubmed-meshheading:12067561-Receptors, CCR3,
pubmed-meshheading:12067561-Receptors, Chemokine,
pubmed-meshheading:12067561-Stereoisomerism,
pubmed-meshheading:12067561-Structure-Activity Relationship
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.
|
|
pubmed:affiliation |
Bristol-Myers Squibb Company, Experimental Station, PO Box 80336, Wilmington, DE 19880-0336, USA. dean.wacker@bms.com
|
|
pubmed:publicationType |
Journal Article
|
